Investor Presentation October – December 2024




Forward looking statements and non-IFRS measures

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for gualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. The terms 'Group' and 'Smith+Nephew' are used for convenience to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Certain items included in 'trading results', such as such as trading profit, trading profit margin, trading attributable profit, tax rate on trading results (trading tax expressed as a percentage of trading profit before tax), Adjusted Earnings Per Ordinary Share (EPSA), trading cash flow, free cash flow, trading profit to trading cash conversion ratio, leverage ratio, and underlying revenue growth are non-IFRS financial measures. The non-IFRS financial measures in this announcement are explained and, where applicable, reconciled to the most directly comparable financial measure prepared in accordance with IFRS in our Second Quarter and Half Year 2024 Results announcement dated 1 August 2024.

[◊] Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

S_N





100

Smith+Nephew is a portfolio medical technology business that has been trading for over 160 years, and operates in more than 100 countries

FTSE 100

A constituent of the UK's FTSE 100, with ADRs traded on the New York Stock Exchange

Shares

S+N has a progressive dividend policy, and has paid a dividend every year since 1937

\$5.5bn

Annual sales in 2023 were \$5.5 billion

~18,500

We have around 18,500 employees globally

Our performance















* Underlying growth percentage after adjusting for the effect of currency translation, acquisitions and disposals.

2022

2023

** Proposed dividend of 37.5¢

2019


*** 2020, 2021 2022, and 2023 net debt includes lease liabilities.

2020

2021


A portfolio medical technology business





Leading positions in attractive markets






All market sizes and shares are 2023 estimates. These are generated by Smith+Nephew, based on publicly available sources and internal analysis, and represent an indication of market shares and sizes.

Solid long-term demand drivers intact






The right to win across all business units



Orthopaedics

- + Full range across hips and knees
- Differentiated implant technology, e.g. JOURNEY^o II, OXINIUM^o, OR30^o, EVOS^o
- Robotic enabling technology, CORI^o continuing to extend its functionality

Sports Medicine & ENT



- + Complete offering of Joint Repair, Tower, customer service
- + Leadership positions across key Sports Medicine segments
- + Scaleable synergies with other areas, through CORI and ASCs

Advanced Wound Mgmt.



- Broadest portfolio of solutions covering all key wound types
- + Leading NPWT platform with market expansion potential
- Strong evidence base, distinguishing from value segment

12-Point Plan as driver of growth and productivity





Review of 12-Point Plan as at H1 2024

Transformation across wide range of initiatives





LIFR = Line Item Fill Rate: percentage of customer order lines filled




Acceleration followed improvement in KPIs; progress beyond initial targets show new ways of working becoming embedded





Continuing the strength of Sports Med and AWM






Sports Medicine underlying revenue growth*

🔶 Market growth rate

* Representing repair products and arthroscopic enabling technologies, excluding ENT

- Precise, targeted approach to engagement from deep understanding of customers
- Consistent innovation across procedures and capital
- Complete offering across Joint Repair, the Arthroscopic Tower, and close customer service
- Future drivers: REGENETEN including expansion to Foot and Ankle; continued innovation across consumables and arthroscopic tower

AWM underlying revenue growth



- Focus on portfolio breadth and evidencebased selling
- Continued strong performance in foams and anti-infectives
- Good growth in AWD led by our market leading single-use NPWT device, PICO
- **Future drivers:** Grafix PLUS; ongoing RENASYS EDGE roll out

Higher growth underpinned by innovation delivery





Underlying revenue growth 2016-23



Continued high cadence of product launches

CATALYSTEM

- New short Hip stem, designed for the increasingly preferred direct anterior approach. Launch planned for H2 2024
- First cases completed during Q3 2024. Positive initial surgeon feedback on precision, efficiency and reproducibility

CORI CORIOGRAPH

 Makes CORI the only orthopaedic robotic-assisted system to offer both image-free and image-based registration, according to surgeon preference

Adding next wave of innovative devices

Acquisition of CartiHeal completed in January 2024

- Adds CARTIHEAL AGILI-C, a novel technology for cartilage regeneration
- Indication including patients with mild to moderate OA, as well as the ~700,000 receiving cartilage repair annually in the US

Full US Commercial Launch of AETOS in Q2 2024

+ Follows initial launch in June 2023

Mid-term growth uplift across multiple segments



Moving to higher mid-term growth vs history

	Performance drivers					
Trauma & Extremities	 Share gain in Plates & Screws Expansion into Shoulder replacement 	EVOS, AETOS				
Other Reconstruction	+ Accelerated robotics adoption and deployments	CORI				
ENT	 COBLATION penetration in tonsillectomy Shift of tympanostomies to in-office 					
Sports Medicine: Joint Repair & AET (ex-VBP)	+ Continued launches across categories	REGENETEN CARTIHEAL AGILI-C				
Advanced Wound Devices	 Contract wins in traditional negative pressure Continued single-use market expansion 	RENASYS EDGE				

c.50% of group revenue in segments with outlook of higher growth

.....


•....

Maintaining or recovering performance

	Performance drivers	Highlighted projects	
Knees & Hips	Improved execution through 12-Point Plan		
Advanced Wound Care		Next-gen mechanisms	
Advanced Wound Bioactives	 Maintaining performance through continuous innovation 	Next-gen mechanisms	

Capital allocation framework








Q3 2024 summary revenue performance

Growth by Business Unit*





* Growth rates are versus Q3 2023

** Other Recon includes robotics capital sales, joint navigation and bone cement

Orthopaedics

Revenue of \$549m:

+2.3% underlying*

+2.4% reported

Positive growth in both of US Hips and Knees; weak quarter in China, lower T&E set sales

-

O3 sales factors

+ Global Knees and Hips -0.9% and +4.0%:


- US Knees and Hips +0.7% and +3.2%, showing benefit of operational improvements under the 12-Point Plan
- OUS Knees and Hips -2.8% and +5.0%. Continued solid performance in established markets; c. 5% headwind from slower China
- + Other Reconstruction +13.7%, reflecting robotics capital and consumables growth

+ Trauma & Extremities +3.3%:

 Continued strong momentum for EVOS^{\$}; offset by a slower quarter for legacy systems and sales of full trauma sets

Near-term growth drivers

- Continued flow through of 12-Point Plan improvements in US Recon; rollout of CATALYSTEM[◊] Hip System
- + AETOS^{\$} Shoulder System capital deployment and customer conversions






Sports Medicine & ENT

Continued strong business unit performance excluding VBP





Q3 sales factors

+ Sports Medicine Joint Repair +0.1%:

- +9.4% ex-China; continued strong growth from REGENETEN^{\diamond} in rotator cuff
- China headwind reflects strong price headwind from VBP implementation

+ AET +15.0%:

 Strong growth across arthroscopic tower categories and from WEREWOLF[◆] FASTSEAL; also reflects soft prior year comp

+ ENT -6.8%:

• Reflects very strong prior year comp; return to more normalized growth expected in Q4

Near-term growth drivers

- + Further market penetration of REGENETEN and product expansion to foot and ankle
- + Continued high cadence of innovation across consumables and arthroscopic tower

Advanced Wound Management

Broad-based growth across regions and categories



Revenue of \$422m: +6.5% underlying* +6.5% reported



Q3 sales factors

+ Advanced Wound Care +3.4%:

* Led by ALLEVYN \diamond family of foam dressings; good growth from anti-infectives

+ Advanced Wound Bioactives +8.0%:

- Double-digit growth in skin substitutes following launch of GRAFIX PLUS
- Market behaviour largely unchanged ahead of LCD implementation

+ Advanced Wound Devices +11.0%:

• Strong growth from both PICO^{\diamond} and RENASYS^{\diamond} in Negative Pressure Wound Therapy; good quarter from LEAF^{\diamond} Patient Monitoring System

Near-term growth drivers

- + Continued ramp of new skin substitute version GRAFIX PLUS $^{\diamond}$
- + Ongoing US and Europe roll-out of next-generation NPWT device RENASYS EDGE



Outlook

Growth and margin guidance updated for China headwind



+ 2024 underlying revenue growth of around 4.5%

- Q4 acceleration from continued Recon improvement (ex. China), stronger T&E, 2 extra trading days
- Below previous range, primarily reflecting China remaining slow

+ 2024 trading margin expansion of up to 50bps


- Margin expansion from 12-Point Plan savings, with reduced operating leverage from slower revenue growth
- Continuing to target around 85% trading cash conversion

+ 2025 trading margin of 19.0%-20.0%

- 2025 margin expansion from operating leverage, manufacturing and opex savings
- Updated view reflects expected 2024 baseline, and uncertainty around ongoing China headwinds



Appendices



Technical guidance for FY 2024



	Octob	er 2024	
Foreign exchange and acquisitions			
Translational FX impact on revenue $growth^{(1)}$	c. (0	0.4)%	
Acquisition impact on revenue growth		-	
Non-trading items			
Restructuring costs ⁽²⁾	c. \$95-100m		
Acquisition and integration	\$5-10m		
European Medical Device Regulation (MDR) compliance costs	\$10-15m		
Amortisation of acquisition intangibles & goodwill impairment	\$230-235m		
Other	Adjusted	Reported	
Income/(loss) from associates ⁽³⁾	\$10-15 m	\$(5)-(10)m	
Net interest ⁽⁴⁾	c. \$125m	c. \$125m	
Other finance costs	\$5-10m	\$20-25m	
Tax rate on trading result	19-20%		

(1) Based on the foreign exchange rates prevailing on 25 October 2024(2) Includes c.\$15m of costs expected to be recognised in 2025

(3) Based on analyst consensus forecasts for associate and considering management guidance issued on 6 August 2024
 (4) Includes interest associated with IFRS 16 Leases

Revenue analysis by Business Unit



	2023					2024			
	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q4 Growth %	Full Year Growth %	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q3 Revenue \$m
Orthopaedics	3.9	5.8	8.3	4.9	5.7	4.4	5.8	2.3	549
Knee Implants	5.0	7.8	5.7	3.6	5.5	1.7	2.1	(0.9)	222
Hip Implants	4.6	3.4	3.5	3.6	3.8	3.4	4.0	4.0	146
Other Reconstruction	19.7	21.0	58.5	19.0	28.0	18.0	17.8	13.7	33
Trauma & Extremities	(0.8)	2.5	10.4	5.8	4.4	7.8	11.8	3.3	148
Sports Medicine & ENT	10.0	12.0	11.1	7.1	10.0	5.5	7.6	3.9	441
Sports Medicine Joint Repair	7.3	12.5	11.3	8.8	9.9	7.7	6.0	0.1	232
Arthroscopic Enabling Technologies	9.1	4.6	1.7	3.7	4.7	1.0	8.7	15.0	154
ENT	30.8	38.9	40.2	10.7	29.8	9.0	11.6	(6.8)	55
Advanced Wound Management	7.9	6.2	3.6	7.8	6.4	(2.0)	3.3	6.5	422
Advanced Wound Care	1.0	2.7	3.2	1.4	2.1	(0.5)	3.0	3.4	190
Advanced Wound Bioactives	15.2	3.1	(4.8)	12.5	6.2	(9.8)	0.7	8.0	140
Advanced Wound Devices	12.9	21.4	21.3	14.9	17.6	8.7	8.0	11.0	92
Total	6.9	7.8	7.7	6.4	7.2	2.9	5.6	4.0	1,412

All revenue growth rates are on an underlying basis and without adjustment for number of selling days.

Revenue analysis by region



			2023			2024			
	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q4 Growth %	Full Year Growth %	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q3 Revenue \$m
US	11.8	6.3	7.2	6.2	7.8	(0.6)	3.6	4.0	748
Other Established Markets ⁽¹⁾	7.0	8.5	7.8	6.1	7.3	4.8	6.9	6.8	414
Established Markets	10.0	7.1	7.4	6.2	7.6	1.3	4.8	5.0	1,162
Emerging Markets	(7.3)	11.0	9.2	7.6	5.1	11.6	9.5	(0.1)	250
Total	6.9	7.8	7.7	6.4	7.2	2.9	5.6	4.0	1,412

(1) Other Established Markets are Australia, Canada, Europe, Japan and New Zealand. All revenue growth rates are on an underlying basis and without adjustment for number of selling days

Q3 consolidated revenue analysis by Business Unit



	Q3 2024	Q3 2023	Reported growth	Underlying growth	Acquisitions/ disposals	Currency impact
	\$m	\$m	%	%	%	%
Orthopaedics	549	536	2.4	2.3	-	0.1
Knee Implants	222	223	(0.9)	(0.9)	-	0.0
Hip Implants	146	141	4.1	4.0	-	0.1
Other Reconstruction	33	29	13.8	13.7	-	0.1
Trauma & Extremities	148	143	3.5	3.3	-	0.2
Sports Medicine & ENT	441	425	3.7	3.9	-	(0.2)
Sports Medicine Joint Repair	232	232	(0.2)	0.1	-	(0.3)
Arthroscopic Enabling Technologies	154	134	15.0	15.0	-	0.0
ENT	55	59	(6.7)	(6.8)	-	0.1
Advanced Wound Management	422	396	6.5	6.5	-	0.0
Advanced Wound Care	190	183	3.5	3.4	-	0.1
Advanced Wound Bioactives	140	130	7.9	8.0	-	(0.1)
Advanced Wound Devices	92	83	11.0	11.0	-	0.0
Total	1,412	1,357	4.0	4.0	-	0.0

Trading days per quarter



	Q1	Q2	Q3	Q4	Full year
2021	64	64	63	60	251
2022	64	63	63	60	250
2023	64	63	63	60	250
2024	63	64	63	62	252
2025	62	63	63	63	251

